Skip to main content
Journal of Patient-Reported Outcomes
Fig. 1 | Journal of Patient-Reported Outcomes

Fig. 1

From: Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors

Fig. 1

Median CIPN patient-reported and composite measure scores by PRO-CTCAE item response category at T3. a PRO-CTCAE numbness and tingling severity item. a Differences in median QLQ-CIPN20 Sensory, QLQ-CIPN20 Motor, 0–10 worst CIPN pain intensity NRS (n = 138), and TNSc© scores (n = 118) by PRO-CTCAE Numbness and Tingling Severity Item Score at T3. Severity = 0; TNSc© n = 33; QLQ-CIPN20 and worst pain measures n = 40. Severity = 1; TNSc© n = 49; QLQ-CIPN20 and worst pain measures n = 54. Severity = 2; TNSc© n = 33; QLQ-CIPN20 and worst pain measures n = 38. Severity ≥ 3; TNSc© n = 3; QLQ-CIPN20 and worst pain measures n = 6. b PRO-CTCAE Numbness and Tingling Interference Item. b Differences in median QLQ-CIPN20 Sensory, QLQ-CIPN20 Motor, 0–10 worst CIPN pain intensity NRS (n = 138), and TNSc© scores (n = 118) by PRO-CTCAE Numbness and Tingling Interference Item Score at T3. Interference = 0; TNSc© n = 69; QLQ-CIPN20 and worst pain measures n = 83. Interference = 1; TNSc© n = 34; QLQ-CIPN20 and worst pain measures n = 36. Interference ≥ 2; TNSc© n = 15; QLQ-CIPN20 and worst pain measures n = 19

Back to article page